# SV Health Investors SV Health Investors is a Private Equity based in London, United Kingdom. ## Overview - **Organization type:** Private Equity - **Headquarters:** London, United Kingdom - **Region:** Europe - **Address:** 71 Kingsway, London, WC2B 6ST, UK - **Founded:** 1993 - **Assets under management:** Undisclosed - **Website:** www.svhealthinvestors.com - **LinkedIn:** https://www.linkedin.com/company/sv-health-investors ## Regulatory record - **Reports private funds:** No ## About SV Health Investors is a global private equity and venture capital investment platform with specialized and diversified healthcare funds spanning all sectors and stages. Three teams focus on biotechnology (including dementia), healthcare growth equity and medtech. It is a private investment firm dedicated to investments in the healthcare and life sciences sectors, with a long track record in the US and UK and teams based in Boston and London. ## Sectors - Biotechnology - Healthcare Services - Digital Health - Medical Devices ## Offices - Boston, MA, United States ## People - Kate Bingham — Managing Partner, Therapeutics - Michael Balmuth — Managing Partner, Healthcare Growth - Tom Flynn — Managing Partner, Healthcare Growth - Paul LaViolette — Managing Partner, Medtech - Greg Madden — Managing Partner, Medtech, Healthcare Growth - Nikola Trbovic — Managing Partner, Therapeutics ## Questions ### How is SV Health Investors structured across its investment strategies? SV operates three dedicated verticals, each with its own investment team and fund structures. The Therapeutics group manages early- to late-stage biotech funds — including a Dementia Discovery Fund — while the Healthcare Growth team provides growth capital and liquidity to services, medical products, and digital health companies. The Medtech Convergence Fund focuses on novel medical devices and remote-monitoring technologies. ### In which geographies does SV Health Investors deploy capital? SV invests primarily in the United States and Europe, with offices in Boston and London. Its portfolio and exited investments reflect a transatlantic footprint — companies such as AeroCare Holdings and Insulet originated in the US, while firms like Convergence Pharmaceuticals and Solexa Ltd were based in Europe. ### Who leads the investment decisions at SV Health Investors? Managing Partners Kate Bingham and Laurence Barker co-lead the Therapeutics team, Michael Balmuth and Tom Flynn head Healthcare Growth, and Paul LaViolette and Greg Madden oversee Medtech and Healthcare Growth. Senior Partners such as Mike Ross and Eugene Hill also shape strategy across the platform. ### Does SV Health Investors manage a dedicated dementia fund? Yes. SV runs a standalone Dementia Discovery Fund (DDF) within its Therapeutics vertical. The DDF has its own Scientific Advisory Board of experts, including Maria Carrillo, Chief Science Officer of the Alzheimer's Association, and operates alongside the firm's broader biotech funds. ### What is SV Health Investors' track record on exits? The firm reports 75 IPOs and M&A exits over its history. Disclosed realized investments include Alector, Insulet, Ophthotech (now Iveric bio), Shire Pharmaceuticals, and Solexa Ltd — spanning biotech, medical devices, and specialty pharmaceuticals. ### Does SV Health Investors participate in fund commitments or only direct deals? SV manages dedicated funds across its three verticals and invests directly into companies. It does not market itself as a fund-of-funds, but its Growth Fund Advisory Board and operating-partner network suggest capital is deployed alongside co-investors directly into healthcare operating companies. ## Related profiles - [SVG Capital](https://altss.com/profile/svg-capital) - [Sviluppo Imprese Centro Italia](https://altss.com/profile/sviluppo-imprese-centro-italia) --- Last updated: 2026-08-11T15:08:18.003Z Canonical page: https://altss.com/profile/sv-health-investors Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology